4-Substituted Catechol Tau Aggregation Inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tau aggregation inhibitors are insufficient in inhibiting tau aggregation in cells, which limits their effectiveness in treating tauopathies such as Alzheimer's disease.
Innovation Solution
A tau aggregation inhibitor comprising a 4-substituted catechol structure compound with an electron-donating substituent at position 4 of its catechol ring, or its salt, which effectively prevents and treats tauopathies by suppressing tau aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional tau aggregation inhibitors (naphtho quinone compounds, catechol rings, hydroxytyrosol) are used, then some inhibition of tau aggregation is achieved, but the inhibition is insufficient to properly treat tauopathies
Solution Approach 1:
The patent modifies the catechol ring structure by introducing specific substituents at defined positions (4-position with electron-donating groups, 3-position with electron-withdrawing groups) to optimize tau aggregation inhibition effectiveness. This systematic parameter change in molecular structure transforms conventional inhibitors with insufficient activity into compounds that effectively suppress tau aggregation in cells, directly resolving the reliability issue while maintaining reasonable structural complexity
Solution Approach 2:
The invention creates composite molecular structures by combining multiple functional groups (electron-donating substituents, electron-withdrawing substituents, catechol ring) into a single integrated compound. This composite approach synergistically enhances the inhibition capability beyond what individual components achieve alone, enabling effective tau aggregation suppression that conventional single-function compounds cannot achieve
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
Provided is a tau aggregation inhibitor which can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).